Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002516|
Recruitment Status : Unknown
Verified January 2010 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : May 5, 2004
Last Update Posted : September 17, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma.
PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
|Condition or disease||Intervention/treatment||Phase|
|Sarcoma||Biological: dactinomycin Drug: cyclophosphamide Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: mesna Drug: vincristine sulfate Procedure: conventional surgery Radiation: low-LET cobalt-60 gamma ray therapy Radiation: low-LET photon therapy||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92]|
|Study Start Date :||July 1992|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002516
|Royal Victoria Infirmary|
|Newcastle-upon-Tyne, England, United Kingdom, NE1 4LP|
|Study Chair:||Heribert F. Juergens, MD||University Hospital Muenster|
|Study Chair:||Alan W. Craft, MD||Newcastle-upon-Tyne Hospitals NHS Trust|